In this study, we showed that stool methylated SEPT9 test had high sensitivities (66.7 and 86.7%) in detecting AA and stage I CRC (Table 2), suggesting that stool methylated SEPT9 test could identify more AA patients than Cologuard and methylated SDC2 test (Lee et al., 2014;Niu et al., 2017), and its performance in detecting stage I CRC was comparable to that of Cologuard (Imperiale et al., 2014). The gene discussed is SDC2; the disease is colorectal carcinoma.